Allovir Inc (ALVR NASDAQ) stock market data APIs
$0.422
0.02(5%)
as of January 14, 2025
Allovir Inc Financial Data Overview
Price chart is built with
Anychart
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Prev. Close
0.4
Open
0.422
Volume
216 K
High
0.439
Low
0.3851
52 wk Range
0.3821-1.05
Market Cap
85 255 K
Shares Outstanding
115 M
Revenue
0
EPS
-0.0358
Beta
0.741
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Allovir Inc data using free add-ons & libraries
Get Allovir Inc Fundamental Data
Allovir Inc Fundamental data includes:
- Net Revenue: 0
- EBITDA: -120 465 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-01
- EPS/Forecast: -0.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Allovir Inc News
New
Are Medical Stocks Lagging AlloVir (ALVR) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has AlloVir, Inc. (ALVR) been one of those stocks this year? A qu...
Down -72.39% in 4 Weeks, Here's Why You Should You Buy the Dip in AlloVir, Inc. (ALVR)
A downtrend has been apparent in AlloVir, Inc. (ALVR) lately with too much selling pressure. The stock has declined 72.4% over the past four weeks. However, given the fact that it is now in oversold t...
Karuna downgraded, Arm target raised: Wall Street's top analyst calls
Karuna downgraded, Arm target raised: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls t...
Nike downgraded, Waste Management upgraded: Wall Street's top analyst calls
Nike downgraded, Waste Management upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research c...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
